Allarity Says Initial Data Show Improved Clinical Benefit In Breast Cancer Patients Selected Via Companion Diagnostic
Portfolio Pulse from Vandana Singh
Allarity Therapeutics Inc (NASDAQ:ALLR) announced initial results from its European Phase 2 clinical trial evaluating the efficacy of Ixempra in metastatic breast cancer patients. The study showed promising signs of clinical benefit in four out of four evaluable cases. Ixempra was initially developed by Bristol Myers Squibb & Co (NYSE:BMY) and is approved for metastatic breast cancer patients in the U.S. The initial data suggest that the DRP-Ixempra CDx may identify a subset of patients who potentially have an improved ORR and CBR compared to monotherapy efficacy.
July 05, 2023 | 4:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Allarity Therapeutics' stock price may increase due to promising initial results from its Phase 2 clinical trial.
Positive clinical trial results often lead to an increase in the stock price of the company conducting the trial.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Bristol Myers Squibb's stock price may be indirectly affected as they initially developed Ixempra.
While Bristol Myers Squibb initially developed Ixempra, the current trial is being conducted by Allarity Therapeutics, so the impact on BMY's stock price may be indirect.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50